MedTrace Logo

Cell Repair in Heart Failure

NCT00285454 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-03-31

No results posted yet for this study

Summary

Many people in the UK have ischaemic heart disease. Insufficient blood supply to the heart muscle means that it functions inefficiently, and leads to symptoms of shortness of breath, chest pain and excess fluid in the body. Recently it has been shown that cells from the inside of bone are able to produce many different cell types. We are investigating a new treatment in which a patient's bone marrow cells are taken, and injected into the heart in an attempt to produce new blood vessels and heart muscle cells. This may lead to a new treatment for ischaemic heart disease.

Conditions

Interventions

PROCEDURE

Retrograde coronary venous delivery of cells.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Eric WF Alton · The Department of Gene Therapy, The NHLI Imperial College London

  • Jonathan R Clague · The Royal Brompton Hospital London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-02-28
Completion
2008-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285454 on ClinicalTrials.gov